<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>35(3)</volume><submitter>Schwartz J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>There are only limited data to guide the management of infectious risk for &lt;i>Pneumocystis jiroveci&lt;/i> pneumonia (PCP) in patients with inflammatory bowel disease (IBD). We evaluated the frequency of admissions for PCP among patients with IBD, as well as the temporal trend in PCP admission rates and the contribution of non-IBD risk factors to the development of infection.&lt;h4>Methods&lt;/h4>The National Inpatient Sample from 2016-2017 was queried for all admissions involving both PCP and either Crohn's disease or ulcerative colitis. Inpatient outcomes associated with PCP and additive risk factors for development of PCP within the IBD patient population were assessed using multivariate regression. Linear regression was performed on data from 2002-2017 to measure infectious t</pubmed_abstract><journal>Annals of gastroenterology</journal><pagination>260-266</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9062846</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comprehensive National Inpatient Sample data reveals low but rising &lt;i>Pneumocystis jiroveci&lt;/i> pneumonia risk in inflammatory bowel disease patients.</pubmed_title><pmcid>PMC9062846</pmcid><pubmed_authors>Feuerstein JD</pubmed_authors><pubmed_authors>Stein DJ</pubmed_authors><pubmed_authors>Schwartz J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comprehensive National Inpatient Sample data reveals low but rising &lt;i>Pneumocystis jiroveci&lt;/i> pneumonia risk in inflammatory bowel disease patients.</name><description>&lt;h4>Background&lt;/h4>There are only limited data to guide the management of infectious risk for &lt;i>Pneumocystis jiroveci&lt;/i> pneumonia (PCP) in patients with inflammatory bowel disease (IBD). We evaluated the frequency of admissions for PCP among patients with IBD, as well as the temporal trend in PCP admission rates and the contribution of non-IBD risk factors to the development of infection.&lt;h4>Methods&lt;/h4>The National Inpatient Sample from 2016-2017 was queried for all admissions involving both PCP and either Crohn's disease or ulcerative colitis. Inpatient outcomes associated with PCP and additive risk factors for development of PCP within the IBD patient population were assessed using multivariate regression. Linear regression was performed on data from 2002-2017 to measure infectious t</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May-Jun</publication><modification>2025-04-21T23:13:52.266Z</modification><creation>2025-04-05T19:06:16.71Z</creation></dates><accession>S-EPMC9062846</accession><cross_references><pubmed>35599933</pubmed><doi>10.20524/aog.2022.0713</doi></cross_references></HashMap>